Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sensory-Neural Hearing Loss As an Early Rebound Relapse After Fingolimod Cessation in Multiple Sclerosis Publisher



Moghadasi AN1 ; Poursadeghfard M2 ; Kazemi T3 ; Hosseini S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  3. 3. Otolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran
  4. 4. Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Iranian Journal of Otorhinolaryngology Published:2020


Abstract

Introduction: Multiple sclerosis (MS) is a lifelong disease of the brain and spinal cord. Fingolimod is an oral drug which modulates the S1P receptor and is used for relapsing remitting form of MS and can causes rebound activity if it is ceased even in a short period of washout time. Case Report: Here, we introduce a young girl, a known case of MS, who developed reversible isolated unilateral sensory-neural hearing loss along imaging activity two weeks after stopping fingolimod. The patient responded well to the intravenous corticosteroid therapy which is the first line treatment of new MS attack. Conclusion: fingolimod cessation can cause rebound activity in a short period of the time. It is important to consider any new neurological sign and symptom as a rebound activity during washout time. Although SNHL is not common in MS, it could be presented as an unusual manifestation of rebound relapse after stopping fingolimod. © 2020 Mashhad University of Medical Sciences. All rights reserved.
Related Docs
View other Related Docs
1. Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders, Neurochemical Research (2024)
2. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (Menactrims), Current Medical Research and Opinion (2015)
3. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: 2019 Revisions to the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2020)
4. Characterization of Cd4+ and Cd8+ T Cell Subsets and Interferon Regulatory Factor 4 (Irf4) in Ms Patients Treated With Fingolimod (Fty-720); a Follow-Up Study, Iranian Journal of Allergy# Asthma and Immunology (2018)
5. Iranian Specialists’ Approach to Surgery in Patients With Multiple Sclerosis, Current Journal of Neurology (2023)
6. A Comprehensive Review on the Treatment Approaches of Multiple Sclerosis: Currently and in the Future, Inflammation Research (2019)
7. A Systematic Review of Drugs in Late-Stage Development for the Treatment of Multiple Sclerosis: A Focus on Oral Synthetic Drugs, Inflammation and Allergy - Drug Targets (2015)
8. Incidence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Treated With Fingolimod: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (5)
Mehdi Shafee Ardestani (2)
Other Related Docs
9. Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 Revision of the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2024)